While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
<iframe src="https://statesidedaily.com/embed/cluster/6cbcc59ee053c95b5d39d43f86910d4a4f7ba95d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak"></iframe>
